Patterns of gene expression and allele-specific expression vary among macular tissues and clinical stages of Age-related Macular Degeneration

Charles Zhang[1#,] Julie L. Barr[1,2#], Leah A. Owen[3,4,5,6], Akbar Shakoor[3], Albert T. Vitale[1], John H Lillvis[1,6], Parker Cromwell[1], Nadine Husami[1], Robert Finley[1], Davis Ammar[7], Elizabeth Au[1], Neena B. Haider[8], Rylee A. Zavala[1], Elijah C. Graves[1], Mingyao Li[9], Amany Tawfik[10,11], Sarah X. Zhang[1,2,12], Dwight Stambolian[13], Michael H. Farkas[1,2,12,14], Ivana K. Kim[14], Richard M. Sherva[15], Lindsay A. Farrer[15, 16, 17, 18], Margaret M. DeAngelis[1,2,3,4,6,12,14]*

1. Department of Ophthalmology, Ross Eye Institute, Jacobs School of Medicine and Biomedical Sciences, State University of New York, University at Buffalo, Buffalo, NY 14203, USA.
2. Neuroscience Graduate Program, Jacobs School of Medicine and Biomedical Sciences, State University of New York, University at Buffalo, Buffalo, NY 14203, USA.
3. Department of Ophthalmology and Visual Sciences, University of Utah School of Medicine, The University of Utah, Salt Lake City, UT 84132, USA.
4. Department of Population Health Sciences, University of Utah School of Medicine, The University of Utah, Salt Lake City, UT 84132, USA.
5. Department of Obstetrics and Gynecology, University of Utah School of Medicine, The University of Utah, Salt Lake City, UT 84132, USA.
6. Veterans Administration Western New York Healthcare System, Buffalo, NY 14212, USA.

7. Lion's Eye Institute for Transplant and Research Foundation, Inc, Tampa, FL, 33605, USA.
8. Department of Ophthalmology, Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
9. Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
10. Department of Foundational Medical Studies and Eye Research Center, Oakland University William Beaumont School of Medicine, Rochester, MI 48309, USA.
11. Eye Research Institute, Oakland University, Rochester, MI 48309, USA.
12. Department of Biochemistry, Jacobs School of Medicine and Biomedical Sciences, State University of New York, University at Buffalo, Buffalo, NY 14203, USA.
13. Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
14. Genetics, Genomics and Bioinformatics Graduate Program, Jacobs School of Medicine and Biomedical Sciences, State University of New York, University at Buffalo, Buffalo, NY 14203, USA.
15. Retina Service, Massachusetts Eye & Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
16. Department of Medicine (Biomedical Genetics), Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
17. Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.

18. Department of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
19. Department of Ophthalmology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA

*Corresponding author: **Dr. Margaret DeAngelis, Jacobs School of Medicine and Biomedical Sciences Buffalo NY, 14214 (mmdeange@buffalo.edu)**

#These authors contributed equally this work and therefore are both first authors

Authors emails:

czhang62@buffalo.edu (C.Z.), jbarr2@buffalo.edu (J.L.B.), leah.owen@hsc.utah.edu (L.A.O.), akbar.shakoor@hsc.utah.edu (A.S.), jhlillvi@buffalo.edu (J.H.L.), nadinehu@buffalo.edu (N.H.), parkercr@buffalo.edu (P.C.), rfinley2@buffalo.edu (R.F.), elizabethdgeorge@gmail.com (E.A), gravee1@unlv.nevada.edu (E.C.G), zavalr2@unlv.nevada.edu (R.A.Z.), mingyao@pennmedicine.upenn.edu (M.L.), xzhang38@buffalo.edu (S.X.Z.), amtawfik@oakland.edu (A.T), ivana_kim@meei.harvard.edu (I.K.K), farrer@bu.edu (L.A.F.), sherva@bu.edu (R.M.S.), mhfarkas@buffalo.edu (M.H.F.), stamboli@pennmedicine.upenn.edu (D.S.), albert.vitale@hsc.utah.edu (A.V)., dammar@lionseyeinstitute.org (D.A.)

Abstract

Age-related macular degeneration (AMD) is a complex neurodegenerative disease and is the leading cause of blindness in the aging population. Early AMD is characterized by drusen in the macula and causes minimal changes in visual function. The later stages are responsible for the majority of visual impairment and blindness and can be either manifest as geographic atrophy (dry) or neovascular disease (wet). Available medicines are directed against the wet form and do not cure vision loss. Therefore, it is imperative to identify preventive and therapeutic targets. As the mechanism for AMD is unclear, we aim to interrogate the disease-affected tissue - the macular neural retina and macular retina pigment epithelium (RPE)/choroid. We investigated differentially expressed genes expression (DEG) across the clinical stages of AMD in meticulously dissected and phenotyped eyes using a standardized published protocol (Owen et al., 2019). Donor eyes (n=27) were obtained from Caucasian individuals with an age range of 60-94 and 63% were male, and tissue from the macula RPE/choroid and macula neural retina were taken from the same eye. Donor eyes were recovered within 6 hours post mortem interval time to ensure maximal preservation of RNA quality and accuracy of diagnosis. Eyes were then phenotyped by retina experts using multi modal imaging (fundus photos and SD-OCT). Utilizing DESeq2, followed PCA, Benjamini Hochberg adjustment to control for the false discovery rate, and Bonferonni correction for the number of paired comparisons: a total of 26,650 genes were expressed in the macula RPE/choroid and/or macula retina among which significant differential expression was found for 1,204 genes between neovascular AMD and normal eyes, 40 genes between intermediate AMD and normal eyes, and 1,194 genes between intermediate AMD and neovascular AMD. A comparison of intermediate AMD versus normal eyes included *TCN2, PON1, IFI6,* GPR123, and *TIMD4* as being some of the most significant DEGs in the macula RPE/choroid. A comparison of neovascular AMD versus normal eyes included *SLC1A2, SLC24A1, SCAMP5, PTPRN, and SEMA7A as* being some of the most significant DEGs in the macula RPE/choroid. Top pathways of DEGs in the macular RPE/choroid identified through Ingenuity Pathway Analysis (IPA) for the comparison of intermediate AMD with normal eyes were interferon signaling and Th1 and Th2 activation, while those for the comparison of neovascular AMD with normal eyes were the phototransduction and SNARE signaling pathways. Allele-specific expression (ASE) in coding regions of previously reported AMD risk loci identified by GWAS (Fritsche et al, 2016) revealed significant ASEs for C3 rs2230199 and CFH rs1061170 in the macula RPE/choroid for normal eyes and intermediate AMD, and for CFH rs1061147 in the macula RPE/choroid for normal eyes and intermediate and neovascular AMD. An investigation of the 34 established AMD risk loci revealed that 75% of them were significantly differentially expressed between normal macular RPE/choroid and macular neural retina, with 75% of these loci showing higher expression in the RPE. Similarly, disease state differences for the GWAS loci were only found to be statistically differentially expressed in the macular RPE/choroid. Moreover, the known coding variants in the previously identified GWAS loci including, *CFH*, *C3*, *CFB*, demonstrated ASE across AMD clinical stages in the macular RPE/choroid and not in the neural retina. These data at the bulk level underscore the importance of the RPE/choroid to AMD pathophysiology. While many bulk RNASeq data sets are publicly available, to the

best of our knowledge this is one of the first publicly available datasets with both maculae RPE/choroid and macula neural retina from the same well phenotyped donor eye(s) where the macula is separated from the periphery. Our findings also underscore the importance of studying both macular tissue types to gain a full understanding of mechanisms leading to AMD. Our results provide insights into underlying biological mechanisms that may differentiate the disease subtypes and into the tissues affected by the disease.

Introduction

Age-related macular degeneration (AMD), the leading cause of blindness in the aging population, is a complex neurodegenerative disease with both intermediate and late forms. The intermediate form is a clinical biomarker that can increase the risk of either of the two advanced forms; neovascular AMD (also referred to as wet AMD) and geographic atrophy (GA). In either form, this condition involves progressive degradation of the macula leading to central vision loss which impairs reading, facial recognition, and driving abilities [1]. Precise mechanisms contributing to disease pathogenesis and why the presence of disease is within the macula as opposed to peripheral regions of the retina remain unclear. Though AMD is phenotypically heterogeneous, the Age-Related Eye Disease Study (AREDS) classifies AMD into four stages based on the number and size of drusen in addition to observable pathological abnormalities, such as the sharp loss of pigmentation characteristic of geographic atrophy. These stages are denoted AREDS 1 (no AMD/normal aging), AREDS 2 (early AMD), AREDS 3 (intermediate AMD), and AREDS 4 (end-stage/advanced AMD) [2]. Tools used to assist the ophthalmologist in the staging of AMD include fundus imaging and spectral domain optical coherence tomography (SD-OCT) to provide direct visualization and/or high-resolution, non-invasive cross-sectional, enface imaging of the retina/RPE/choroid.

There is no cure for AMD. Neovascular AMD represents a smaller proportion of overall end stage AMD. The development of anti-vascular endothelial growth factor (VEGF) treatment has helped to mitigate visual loss associated with neovascular AMD, though cannot fully restore anatomic or visual integrity [3, 4]. There are no current FDA-

approved therapeutic interventions for dry AMD which represents the majority of the AMD population. Currently the only treatment for intermediate AMD is supplementation of antioxidant AREDS2 formula, which has been demonstrated to modestly reduce the rate of progression to advanced AMD [6]. As yet there are no FDA approved medications for end stage dry AMD, geographic atrophy, although an anti-C3 and anti-C5 agent slowed the growth of geographic atrophy, both increased incidence of neovascular AMD; it is unclear when and if these agonists will be FDA approved [7, 8]. Appropriate therapies that prevent, slow or stop disease progression are clearly needed. Although a study by the International Age-related Macular Degeneration Genomics Consortium (IAMDGC) identified genome-wide significant association at 34 loci [3], most of the significantly associated variants are within non-coding regions (such as introns, gene regulatory regions, or positioned distally from a functional gene) and have no known functional consequences. While this has directed us to potential pathways underlying disease mechanism(s) this has not moved us closer to druggable therapeutic targets for AMD. Therefore, as we and others have previously hypothesized an investigation of well characterized and geographically dissected tissues affected by the disease pathophysiology may be the appropriate first step in ascribing function to a gene in a complex disorder such as AMD [9, 10]. Though gene expression has been examined within tissues affected by AMD, findings have not been consistent between studies [11-17]. Inconsistency between studies whether single cell, single nuclei and/or bulk RNASeq, may include lack of separation of geographical regions (eg. macula retina and/or the macula RPE/choroid from the periphery), a lengthy death to preservation time in the processing of the tissue, and/or lack of pre and/or post-mortem phenotyping

for both eyes within the same donor [10,18, 20]. RNA-Seq is an agnostic and unbiased approach to examine gene expression a priori [21-22]. Additionally, RNA-Seq can uncover differentially spliced genes and long intervening non-coding RNAs (lncRNAs) [23–27]. To date, studies that have employed RNA-Seq [28-30] have not evaluated gene expression in both macula neural retina and macula RPE/choroid within the same donor eye in intermediate and separately neovascular AMD compared to well characterized control donor eyes. We focused the present study on tissues specifically affected by AMD, the macula of the retina pigment epithelium/choroid (RPE)/choroid and the macula of the neural retina, in an effort to ascertain differential gene expression (DEG) between the clinical stages of AMD. To address the complexity of a multi-faceted disease, we utilized a systems biology approach that integrates basic experimental, genomic, phenotypic, and clinical data into a model for understanding AMD disease pathogenesis. [28] We employed a standardized phenotyping protocol within a given donor, of both eyes recovered within 6 hours post mortem [20], the maximum interval to achieve minimal RNA half-life variability [29], enhanced RNA quality [34–36] and because we cannot assume that both normal and diseased tissue degrades at a similar rate. In addition, motivated by previous studies showing evidence of allele-specific expression (ASE) [37] in genes associated with risk of autism, stroke progression, Alzheimer disease and cancer [38-43], we interrogated the DNA of each donor for previously reported AMD GWAS coding variants [5] to determine whether an imbalance of expression between alleles may underlie phenotypic variation and hence the pathophysiology of AMD. To our knowledge, this is the first study to assess ASE across the clinical spectrum of AMD at a genome-wide level.

Methods

The protocol was reviewed and approved by the institutional review board at the University at Utah (IRB 52879) and conforms to the tenets of the Declaration of Helsinki.

Donor Eye Tissue Repository

Methods for human donor eye collection were previously described in detail according to a standardized protocol [20]. In brief, in collaboration with the Utah Lions Eye Bank, donor eyes were procured within a 6-hour post-mortem interval, defined as death-to-preservation time. Both eyes of the donor underwent post-mortem phenotyping with ocular imaging, including spectral domain optical coherence tomography (SD-OCT), and color fundus photography as published. Retinal pigment epithelium/choroid was immediately dissected from the overlying retina, and macula separated from periphery using an 8mm macular punch. For both peripheral and macular tissues, RPE/choroid was separated from the overlying retinal tissue using microdissection; tissue planes were optimized to minimize retinal contamination of RPE/choroid samples using a subsequent 6mm RPE/choroid tissue punch. Post-mortom phenotype was determined as published. In brief, AMD phenotype employed the Age-Related Eye Disease Study severity grading scale, where AREDS category 0/1 was considered normal, AREDS category 3 intermediate AMD, and AREDS category 4b neovascular AMD [44]. Phenotype analysis was performed as described, [24], by a team of 4 retinal specialists and ophthalmologists at the University of Utah School of Medicine, Moran Eye Center

and the Massachusetts Eye and Ear Infirmary Retina Service. Agreement of all 4 specialists upon independent review of the color fundus and OCT imaging was deemed diagnostic; discrepancies were resolved by collaboration between a minimum of three specialists to ensure a robust and rigorous phenotypic analysis. One eye was per donor was biochemically analyzed. In the case of discordant phenotypes within the same donor, the more severe diseased eye was used for inclusion in the study. For example, if a patient had a diagnosis of AREDS 3 in one eye and AREDS 0/1 in the contralateral eye only the AREDS 3 eye was used in the study. Similarly, if a patient had a diagnosis of AREDS 3 in one eye and neovascular AMD in the contralateral eye only the neovascular eye was used in the study. Although AREDS category 2 early AMD, category 4a (geographic atrophy) and AREDS category 4c (both geographic atrophy and neovascular AMD) were collected and ascertained as previously described they were not included in this study [9].

Study Population

Transcriptome profiling from macular retina and RPE/choroid samples from 27 unrelated eye tissue donors was performed using RNA-sequencing. Analyzed donor tissues included one randomly selected eye per donor comprising 10 eyes with intermediate AMD, 5 eyes with neovascular AMD, and 12 normal control eyes. Macular neural retina or RPE/choroid was isolated using the Utah Protocol technique as published by our group [20,45,-46]. In brief, neurosensory retina was isolated using an 8mm punch centered on the fovea and placed in RNAlater (Ambion). RPE/choroid tissue was isolated from overlying neurosensory retina using microdissection and retinal

contamination minimized through isolation of the central 6mm; the tissue was similarly placed in RNAlater [20]. Tissues were stored at 4°C for 24 hours and then placed at -80° C for long term storage.

Nucleic Acid Extraction and RNA-Sequencing

DNA and RNA were extracted from macular retina or RPE/choroid tissues prepared as above using the Qiagen All-prep DNA/RNA mini kit (cat #80204) according to manufacturer's protocol (a total of 54 samples). Quality of RNA samples was assessed with an Agilent Bioanalyzer. Total RNA samples were poly-A selected and cDNA libraries were constructed using the Illumina TruSeq Stranded mRNA Sample Preparation Kit (cat# RS-122-2101, RS-122-2102) according to the manufacturer's protocol. Sequencing libraries (18 pM) were chemically denatured and applied to an Illumina TruSeq v3 single read flow cell using an Illumina cBot. Hybridized molecules were clonally amplified and annealed to sequencing primers with reagents from an Illumina pTruSeq SR Cluster Kit v3-cBot-HS (GD-401-3001). Following transfer of the flowcell to an Illumina HiSeq instrument (HCS v2.0.12 and RTA v1.17.21.3), a multiplexed, 50 cycle single read sequence run was performed using TruSeq SBS v3 sequencing reagents (FC-401-3002).

Primary Processing of RNA Sequencing Data

Each of the 54 sample 50bp, poly-A selected, non-stranded, Illumina HiSeq fastq datasets were processed as follows: reads were aligned using NovoCraft's novoalign 2.08.03 software (http://www.novocraft.com/) with default settings plus the -o SAM -r All

50 options to output multiple repeat matches. The genome index used contained human hg19 chromosomes, phiX (an internal control), and all known and theoretical splice junctions based on Ensembl transcript annotations. Additional details for this aspect of the protocol are described elsewhere (http://useq.sourceforge.net/usageRNA-Seq.html). Next, raw novoalignments were processed using the open source USeq SamTranscriptiomeParser (http://useq.sourceforge.net) to remove alignments with an alignment score greater than 90 (~ 3 mismatches), convert splice junction coordinates to genomic, and randomly select one alignment to represent reads that map equally well to multiple locations. Relative read coverage tracks were generated using the USeq Sam2USeq utility (http://useq.sourceforge.net/cmdLnMenus.html#Sam2USeq) for each sample and sample type (Normal Retina, Intermediate AMD Retina, Neovascular AMD Retina, Normal RPE/choroid, Intermediate AMD RPE, and Neovascular AMD RPE/choroid). These data tracks are directly comparable in genome browsers and good tools to visualize differential expression and splicing. Estimates of sample quality were determined by running the Picard CollectRNA-SeqMetrics application (http://broadinstitute.github.io/picard/) on each sample. These QC metrics were then merged into one spreadsheet to identify potential outliers. Agilent Bioanalyzer RNA integrity number (RIN) and library input concentration columns were similarly added for QC purposes (http://www.genomics.agilent.com). Out of the 54 samples, 48 samples passed QC analysis.

Differential Gene Expression and Splicing Analysis

Sample sets were analyzed using the DefinedRegionDifferentialSeq (DRDS) utility of USeq to detect differentially expressed and differentially spliced genes. This application accepts as input a conditions directory containing folders with biological replicas from each sample type (Normal Retina, Intermediate AMD Retina, Neovascular AMD Retina, Normal RPE, Intermediate AMD RPE, and Neovascular AMD RPE) and an Ensembl gene table in UCSC refFlat format. Gene models were created by merging gene transcripts into a single composite "gene" with the USeq MergeUCSCGeneTable utility. A table containing alignment counts from each sample for each gene was created with DRDS. Data in this table provided the basis for estimating count-based differential abundance using the DESeq2 Bioconductor package (http://www.bioconductor.org/packages/release/bioc/ html/DESeq2.html) [47]. This program estimates the over-dispersion in the count data and calculates p-values using a negative binomial test. The Benjamini-Hochberg p-value correction was applied to control for multiple testing. DESeq2 also generates a log2 ratio estimate of difference in gene abundance using variance corrected counts as well as rLog values for clustering and principal component analysis (PCA). Library size and within replica variance were estimated for each sample. Pairwise comparisons were made between the normal and disease subgroups. Differences in splicing were assessed for merged replica counts for each exon with $\geq$10 counts in each gene in each subgroup by a chi-square test. A Bonferroni multiple testing correction was applied and the exon with the biggest absolute log2 normalized gene count ratio was noted. A per base normalized gene count read coverage log2 ratio graph was created enabling visualization of the relative exon coverage difference for each pairwise comparison. To identify potential outlier

samples, unsupervised hierarchical clustering (HC) and PCA were performed with the aid of the Partek Genomic Suite (http://www.partek.com/pgs) using the default settings. DESeq2 rLog values from genes with ≥20 counts were included in this procedure. For HC visualization, row values were mean centered at zero and scaled to a standard deviation of one.

SNP Genotyping

Genome-wide SNP genotyping was performed on DNA obtained from peripheral blood from each donor eye subject using Illumina's HumanOmni2.5-8 BeadChip Kit according to the manufacturer's protocol **(**http://www.illumina.com/products/humanomni25-8_beadchip_kits.ilmn**).** AMD associated SNPs that were not present on the HumanOmni2.5-8 BeadChip were genotyped using a combination of pre-designed and Custom Taqman SNP Genotyping Assays (Applied Biosystems). Each assay was run in a 15 µl reaction containing 2x Taqman GTXpress master mix, 40x probe, and 10 ng of DNA. Thermal cycling was performed according to the manufacturer's protocol. The ABI 7500 Real-Time PCR System, with the accompanying software, was used to analyze the genotypes.

Differential Expression Validation by Real-Time PCR

RNA was reverse transcribed using oligo-dT primers (Invitrogen) and SuperScript III reverse transcriptase (Invitrogen) according to the manufacturer's protocol. The cDNA was used as a template for real-time PCR reactions run in triplicate using pre-designed Taqman Gene Expression Assays (Life Technologies) for *UCHL1, PFKP, LPCAT1,*

PDPN, GAS1, CST3 and for *UBC* as an endogenous control. Assays were run on the Taqman 7500 Real Time PCR system (Life technologies). Mean Ct values were normalized to *UBC* and analyzed using REST 2009 Software (http://www.gene-quantification.de/rest.html).

Allele-Specific Expression (ASE)

SNPs previously identified by GWAS as being associated with AMD (determined using the GWAS Catalog https://www.ebi.ac.uk/gwas/) [5] were investigated for allele-specific expression (ASE) in our dataset. Specifically, we genotyped the exonic AMD SNPs using either the genotypes from the HumanOmni2.5-8 BeadChip Kit or TaqMan assays. Bam files of individuals showing a heterozygous genotype were examined to determine the number of reads for each of the two alleles. Genotypes of heterozygotes determined from the SNP Chip showing monoallelic expression were confirmed using proxies ($r^2 \geq 0.8$) as determined by the 1000 Genomes phase 3 CEU reference panel. Only individuals with ≥ 10 reads were used. A binomial test, corrected using Benjamini-Hochberg, was used to determine statistically significant allelic imbalance within each individual.[48]

Bioinformatic Analysis

QIAGEN Ingenuity Pathway Analysis (IPA) (QIAGEN Inc., https://digitalinsights.qiagen.com/IPA) was employed to identify pathways our DEGs function in between AMD normal, Intermediate AMD, and Neovascular AMD [49]. Identification of potential pathways associated with protective or risk features was

conducted between the neovascular AMD vs intermediate AMD through direction of log fold changes showing higher expression in tissue associated with either intermediate AMD or neovascular AMD. Genes with higher expression with intermediate AMD were labelled as protective while higher expression in neovascular AMD. The list of protective and risk genes were compared against the genes associated with the significant canonical pathways identified through IPA.

Results

Numbers and characteristics of subjects available for analysis of each tissue type after QC are shown in **Table 1**. For clustering analysis, using both hierarchal clustering (HCA) and principal component analysis (PCA) based on the samples' whole transcriptome expression, samples split into two primary groups comprised of Retina and RPE/choroid samples. Clear separation of RPE/choroid and retina tissue types was observed. Within each tissue type, there was not clear separation between the disease subtypes. Greater variability was observed among the RPE/choroid samples than among the retina samples (**Fig 1**). None of the samples differed substantially to warrant flagging as an outlier.

To evaluate the quality of our tissue dissection we calculated the number of reads mapped to genes known to be expressed exclusively in the neural retina and RPE/choroid, respectively, using an approach as previously described for the retina [61]. Retina genes involved in phototransduction (*GNGT1, GUCA1A, PDE6A, GNB1, CNGB1, GNAT1, CNGA1, PDE6B, PDE6G, PRPH2, RHO, ROM1, SAG*, and *SLC24A1*) accounted for an average of 2.3% of reads in the total normal retina library

and accounted for 0.06% of our normal RPE/choroid tissue reads, proportions which are similar to those reported in a previous study [50]. In our study RPE/choroid genes (*BEST1, RDH5*, and *RPE6*,) accounted for an average of 0.65% of reads in the total RPE/choroid library and only 0.02% of total reads in the retina library. These findings demonstrate that neither the retina or the RPE/choroid is likely contaminated (e.g., if there was contamination of retina genes in the RPE/choroid library, reads would be greater than 1% compared to the observed proportion of 0.06%).

Table 1. Subject Characteristics

Normal				
Group	**n**	**Ave. RIN**	**Age (range)**	**Males (%)**
All Samples (Retina)	12	6.65	74.0 (60-94)	9 (75.0%)
All Samples (RPE/Choroid)	12	6.66	74.0 (60-94)	9 (75.0%)
Clean Samples (Retina)	10	6.76	74.4 (60-94)	8 (80.0%)
Clean Samples (RPE/Choroid)	9	6.93	74.2 (60-94)	7 (77.8%)
Intermediate AMD				
Group	**n**	**Ave. RIN**	**Age (range)**	**Males (%)**
All Samples (Retina)	10	6.89	76.0 (60-87)	6 (60.0%)
All Samples (RPE/Choroid)	10	6.7	76.0 (60-87)	6 (60.0%)
Clean Samples (Retina)	9	6.91	75.0 (60-87)	6 (66.7%)
Clean Samples (RPE/Choroid)	9	6.76	75.0 (60-87)	7 (66.7%)
Neovascular AMD				
Group	**n**	**Ave. RIN**	**Age (range)**	**Males (%)**
All Samples (Retina)	5	6.7	83.4 (74-94)	2 (40.0%)
All Samples (RPE/Choroid)	5	7.06	83.4 (74-94)	2 (40.0%)
Clean Samples (Retina)	5	6.7	83.4 (74-94)	2 (40.0%)
Clean Samples (RPE/Choroid)	5	7.06	83.4 (74-94)	2 (40.0%)

Abbreviations: n, number; Ave., average; RIN, RNA Integrity Number; RPE, Retinal Pigment Epithelium.

Gene Expression Differences

A total of 26,650 genes were expressed in RPE/choroid and/or retina. Within phenotypically documented normal eyes, 16,638 genes showed significant (FDR ≤ 0.05) differential expression between RPE/choroid and retina tissues with a minimum fold change ≥ |1.5|. Within macular RPE/choroid tissues, significant differential expression was observed for 1,204 genes between neovascular AMD and normal eyes, 40 genes between intermediate AMD (AREDS 3) and normal eyes, and 1,194 genes between Intermediate AMD and neovascular AMD eyes (**Fig 2a; S1 Table**). Within macular neural retina tissues, 41 genes were differentially expressed between neovascular AMD and normal eyes, 30 genes between Intermediate AMD and normal eyes, and 50 genes between Intermediate AMD and neovascular AMD eyes (**Fig 2b**). Of these differentially expressed genes, 29 were unique to Intermediate AMD vs. normal RPE/choroid, 285 were unique to neovascular AMD vs. normal, and 276 were unique to intermediate AMD vs. neovascular AMD. Of the 40 significant differentially expressed genes in the normal versus Intermediate AMD RPE/choroid and the 1204 significant differentially expressed genes in the normal versus neovascular AMD RPE/choroid, six genes found in common (**Fig 3**). These six common genes were *MTRN2L1, CLEC2L, CCM2L, CYP4X1, GLDN,* and *SMAD7* (**Fig 3**). The top 10 differentially expressed genes between disease states within the RPE/choroid and Retina are listed in **Table 2a-b**. Of note, the only gene, that overlapped between any RPE/choroid and retina disease comparisons, was mitochondrial-derived peptide humanin (*MTRNR2L1*). *MTRNR2L1* was found to be differentially expressed between the intermediate AMD versus normal state. Of interest in the context of AMD, *MTRNR2L1* has been previously reported to protect human RPE

cells against oxidative stress and restore mitochondrial function *in vitro* [51]. *CHD7* which was found to be downregulated in those with intermediate AMD compared to normal RPE/choroid has been previously associated with AMD in non-smokers by GWAS [52]. *TIMD4*, upregulated in those with intermediate AMD compared to normal RPE is associated with regulation of blood level lipids (*LDL*, cholesterol and triglycerides) at the GWAS level [53-55]. Also noteworthy, a unique lncRNA (*AC000124.1*) was down regulated in intermediate AMD compared to neovascular RPE/choroid, while lincRNA (*RP11-240M16.1*) and *PIWL1* were both upregulated in neovascular AMD compared to normal RPE/choroid (Tables 2 and 2b, respectively). A total of nine unique miRNAs were identified (*MIR146A*, *MIR3918*, *MIR4657*, *MIR17HG*, *MIR3620*, *MIR 3064*, *MIR197*, *MIR4680*, and *MIR4647*) across all disease comparisons. Of these miRNAs, six (*MIR4657*, *MIR17HG*, *MIR3620*, *MIR197*, *MIR3064*, and *MIR3918*) were found to have DEG in intermediate AMD vs neovascular AMD in the RPE/choroid while three (*MIR146A*, *MIR197*, and *MIR3918*) were identified in the neovascular AMD vs normal in the RPE/choroid (**Table S1**). In the retina, two miRNAs were seen, *MIR4680,* in the neovascular vs normal and *MIR4647* in the intermediate AMD vs neovascular AMD (**Table S1**).

Table 2. Top ten significant differentially expressed genes in each disease comparison.

a.

Intermediate AMD vs Normal RPE/choroid			
Gene Name	**Fold Change**	**p-value**	**Function**
MTRNR2L1	59.045	1.75462E-05	Negative regulation of apoptosis
PON1	4.606	0.0003	Calcium ion binding and phospholipid binding
IFI6	3.613	0.0033	Regulation of apoptosis
TIMD4	23.277	0.0033	Enable phosphatidylserine binding activity
GPR123	-3.811	0.0040	G-protein couples receptor activity and transmembrane signaling receptor activity
RN7SKP186	2.105	0.0041	Pseudogene
CDH7	-3.263	0.0128	Calcium ion binding
TCN2	3.753	0.0144	Cobalamin binding
CLEC2L	-4.781	0.0230	Carbohydrate binding
DPP6	-2.197	0.0230	Serine-type peptidase activity
Neovascular AMD vs Normal RPE/choroid			
Gene Name	**Fold Change**	**p-value**	**Function**
RP11-58B17.2	8.857	1.01735E-14	Unknown
RP11-240M16.1	31.631	3.15544E-14	Unknown
SLC1A2	12.297	3.15544E-14	Glutamate transmembrane transporter and symporter activity
SLC24A1	12.288	3.15544E-14	Calcium and potassium/sodium symporter
SCAMP5	7.473	5.13906E-13	Calcium-dependent exocytosis
PTPRN	11.977	7.34743E-13	Phosphatase activity and spectrin binding
RHO	47.223	7.34743E-13	Photoreceptor and G-protein coupled receptor activity
RP11-215G15.5	8.640	1.27666E-12	Unknown
SEMA7A	8.749	2.14117E-12	Integrin binding and signaling receptor activity
CPE	6.373	2.27007E-12	Cell adhesion molecule binding and carboxypeptidase activity
Intermediate AMD vs Neovascular AMD RPE/choroid			
Gene Name	**Fold Change**	**p-value**	**Function**
CALB1	13.385	1.17108E-10	Calcium and vitamin D binding
RP11-58B17.2	-5.688	1.17108E-10	Unknown
AC000124.1	-16.266	8.11468E-10	Unknown
AC114803.3	-9.014	8.11468E-10	Unknown
CADM2	-7.240	8.11468E-10	Synaptic cell adhesion
CHRNB2	-4.518	8.11468E-10	Protein heterodimerization and extracellular ligand gated ion channel activity
PTPRN	-9.354	8.11468E-10	Phosphatase activity and spectrin binding
SEZ6L2	-4.310	8.11468E-10	Endoplasmic reticulum functions in neurons
SLC24A1	-8.444	8.11468E-10	Calcium and potassium/sodium symporter
TM4SF2	-3.642	8.11468E-10	Cellular proliferation and motility

b.

Intermediate AMD vs Normal Retina			
Gene Name	**Fold Change**	**p-value**	**Function**
MTRNR2L1	68.021	0.0000	Negative regulation of apoptosis
ERN1	2.121	0.0038	Degrading misfolded proteins
ANO3	*3.706*	*0.0053*	Calcium-dependent phospholipid scramblase activity
CASP7	*2.223*	*0.0053*	Execution phase of cellular apoptosis
CXCL10	*25.072*	*0.0053*	Signaling receptor binding and chemokine activity
HELZ2	2.847	0.0053	RNA binding and nuclear receptor activity
RNU4-1	*2.566*	*0.0053*	RNA coding associated with the snRNA class
SNORA12	2.126	0.0053	Small non-coding RNA involved in RNA processing
SNORD89	*2.620*	*0.0053*	RNA coding associated with the snoRNA class
SNORA21	*2.573*	*0.0084*	RNA coding associated with the snoRNA class
Neovascular AMD vs Normal Retina			
Gene Name	**Fold Change**	**p-value**	**Function**
NME3	-1.839	3.41E-05	Nucleoside diphosphate kinase activity
CTD-2571L23.6	*-3.642*	*9.41E-05*	RNA gene affiliated with the lncRNA class
MTRNR2L1	62.680	1.00E-04	Negative regulation of apoptosis
RNU11	*3.658*	*0.0004*	RNA gene associated with the snRNA class
RPS25	1.537	0.0005	RNA binding
RN7SKP185	-5.475	0.0008	Small nuclear pseudogene
RPL14P1	1.732	0.0028	Pseudogene
GRIN3B	*-2.177*	*0.0044*	Calcium channel activity and ionotropic glutamate receptor activity
AC083873.4	2.623	0.0103	Unknown
RP11-56B16.5	-2.297	0.0103	Unknown
Intermediate AMD vs Neovascular AMD Retina			
Gene Name	**Fold Change**	**p-value**	**Function**
AC004943.1	9.961	0.0003	Unknown
NME3	1.779	0.0003	Nucleoside diphosphate kinase activity
CTD-2571L23.6	*3.390*	*0.0005*	RNA gene affiliated with the lncRNA class
RP11-90H3.1	-2.179	0.0005	Unknown
RN7SL263P	8.049	0.0006	Pseudogene
AC013470.6	-3.211	0.0015	Unknown
NSA2	-1.662	0.0015	RNA binding
AC010761.8	1.617	0.0020	Unknown
AL353629.1	-2.141	0.0034	Unknown
RPL14P1	-1.725	0.0034	Pseudogene

Analysis of Genes previously associated with AMD

Among genes demonstrated to be associated with AMD risk in previous studies [10,56-57] and the GWAS conducted by the International AMD Genetics Consortium (IAMDGC) [1], expression was statistically significantly *higher* for *ABCA4* (3.1 fold increase, p-value = 0.0001), *ABCA7* (3.4 fold increase, p-value = 0.0018), and *RORA* (1.9 fold increase, p-value = 0.004) in neovascular RPE/choroid tissue compared with normal RPE/choroid tissue (fold change > 2, p-value ≤ 0.01; **Table S1**). *VTN* expression (fold change = 3.3, p-value = 0.02) was also found to be significantly *higher* in neovascular RPE/choroid tissue compared with normal RPE/choroid tissue. Consistent with these results, we found that expression of *ABCA4* (fold change = -3.1, p-value = 0.0002) and *ABCA7* (fold change = -3.2, p-value = 0.0018) was significantly *lower* in intermediate AMD RPE/choroid tissue compared with neovascular RPE/choroid tissue. (fold change > 2, p-value ≤ 0.01). Expression was also found to be significantly *higher* for *TNFRSF10B* (fold change = 1.7, p-value = 0.02) and *TRPM1* (fold change = 1.7, p-value = 0.04) in intermediate AMD RPE/choroid tissue compared with neovascular RPE/choroid tissue. Additionally, *SPEF2* expression (fold change = -1.5, p-value = 0.0165) was significantly *lower* in intermediate AMD RPE/choroid tissues compared to neovascular RPE/choroid tissue. None of the associated AMD risk susceptibility genes were significantly differentially expressed between intermediate AMD and normal RPE/choroid tissues.

Within normal macular tissues, the expression levels of *ABCA4, ABCA7, C10orf88, CYP24A1, NLRP2, PELI3, RORA, RORB, SPEF2, SYN3, TMEM97,* and *VTN* were significantly higher in the neural retina compared to the RPE/choroid,

whereas the levels of *ABCA1, ABHD2, ADAMTS9-AS1, ADAMTS9-AS2, C2, C3, C4A, C9*, *CD63, CETP, CFB, CFH, CFHR3-CFHR1, CFI, CNN2, COL5A1, COL8A1, ITGA7, LIPC, MMP19, MMP9, PCOLCE, PILRA, PKP2, PLA2G4A, RDH5, RGS13, RLBP1, SLC16A8, TGFBR1, TIMP3, TNFRSF10A, TNFRSF10B, TRPM1, TRPM3, TSPAN10, UNC93B1,* and *VDR* were significantly higher in the RPE/choroid compared to the retina (threshold: fold change > 2, p-value ≤ 0.01; **Table S1**). *ARHGAP21, CCT3, HTRA1,* and *SRPK2* were also found to be up-regulated in the neural retina compared to the RPE/choroid, whereas *NPLOC4, RAD51B, ROBO1, SKIV2L,* and *STON1-GTF2A1L* were found to be marginally up-regulated in the RPE/choroid compared to the neural retina (**Table S1**). Overall, of the 34 GWAS loci (5), 75% were found to be statistically differentially expressed between the macular Retina and the macular RPE/choroid, of these genes 75% were significantly upregulated in the RPE/choroid (**Table 3**).

Table 3. Comparisons of tissue expression levels in RPE/Choroid or retina of

Previously Identified AMD Loci	Tissue With Higher Expression (RPE/Choroid or Retina)
C2/CFB/SKIV2L	RPE/Choroid
ARMS2/HTRA1	Retina
SYN3 *	Retina
TIMP3 *	RPE/Choroid
PRLR/SPEF2	RPE/Choroid
PILRB/PILRA	RPE/Choroid
KMT2E/SRPK2	Retina
MIR6130/RORB	RPE/Choroid
RDH5/CD63	RPE/Choroid
CTRB2/CTRB1	RPE/Choroid
TMEM97/VTN	Retina
NPLOC/TSPAN10	RPE/Choroid
ABCA1	RPE/Choroid
ADAMTS9-AS2	RPE/Choroid
COL8A1	RPE/Choroid
C9	RPE/Choroid
TNFRSF10A	RPE/Choroid
TGFRB1	RPE/Choroid
RAD51B	RPE/Choroid
LIPC	RPE/Choroid
CETP	RPE/Choroid
C3	RPE/Choroid
SLC16A8	RPE/Choroid
TRPM3	RPE/Choroid
RORB	Retina
ARHGAP21	Retina
CNN2	RPE/Choroid
MMP9	RPE/Choroid

previously established AMD risk loci among normal RPE/choroid vs normal retina eyes.

Table 3. Shows tissue with higher expression of previously identified AMD loci as identified by Fritsche et al. (2016) for the RPE/Choroid versus the retina in normal eyes. *Identified on the same locus but have differing tissue with higher expression

Pathway Analysis for Differentially Expressed Genes

IPA pathway analysis was conducted on significant differentially expressed genes found in the RPE/choroid across all disease states. For each comparison, the ten most significant pathways for each condition were identified (**Table 4**). When comparing intermediate AMD and normal, 21 significant pathways for significant differentially expressed genes were revealed (**Table 4**). A total of 63 significant pathways were identified when looking into significant differentially expressed genes in neovascular AMD with normal, and 52 significant pathways when comparing neovascular AMD with intermediate AMD (**Table 4**). Interestingly, the calcium signaling pathway was significant across all comparisons, while 47 pathways were in common between the neovascular AMD and normal with the neovascular and intermediate AMD (**Table 4**). A pathway analysis of the six overlapping genes between intermediate AMD and normal with neovascular AMD and normal revealed 14 significant pathways, with BMP signaling and TGF-β signaling being of particular interest. The axonal guidance signaling pathway showed potential protective features with in the intermediate AMD vs neovascular AMD in the RPE/choroid 23% (*ACE2*, *ADAMTS1*, *ADAMTS8*, *BMP8A*, *RND1*, *SEMA4C*, and *WNT16*) of the identified genes being protective in this pathway while 10% (*EPHA10*,

LRRC4C, and *SEMA4B*) shown as risk genes with the remaining 67% of genes in this pathway not being identified.

Table 4. IPA pathway analysis of significant differentially expressed genes in the RPE/Choroid.

Intermediate AMD vs Normal		Neovascular AMD vs Normal		Neovascular AMD vs Intermediate AMD	
Pathway Name	P-Value	Pathway Name	P-Value	Pathway Name	P-Value
Interferon Signaling	2.68E-05	Phototransduction Pathway	1.08E-29	Phototransduction Pathway	8.41E-30
Th1 and Th2 Activation Pathway	1.68E-04	SNARE Signaling Pathway	3.37E-07	SNARE Signaling Pathway	6.06E-08
Th1 Pathway	1.01E-03	Cardiac β-adrenergic Signaling	1.72E-06	Cardiac β-adrenergic Signaling	1.50E-06
nNOS Signaling in Neurons	2.62E-03	G-Protein Coupled Receptor Signaling	5.51E-06	Synaptogenesis Signaling Pathway	2.45E-06
Role of JAK2 in Hormone-like Cytokine Signaling	4.52E-03	Endocannabinoid Neuronal Synapse Pathway	5.69E-06	Protein Kinase A Signaling	5.95E-05
Activation of IRF by Cytosolic Pattern Recognition Receptors	4.96E-03	Role of NFAT in Cardiac Hypertrophy	5.04E-05	GABA Receptor Signaling	6.26E-05
Multiple Sclerosis Signaling Pathway	4.58E-03	Synaptogenesis Signaling Pathway	6.10E-05	Endocannabinoid Neuronal Synapse Pathway	7.18E-05
JAK/STAT Signaling	7.78E-03	GABA Receptor Signaling	6.88E-05	G-Protein Coupled Receptor Signaling	3.81E-04
Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza	8.53E-03	Protein Kinase A Signaling	6.95E-05	Role of NFAT in Cardiac Hypertrophy	3.69E-04
IL-15 Production	1.69E-02	Relaxin Signaling	1.27E-04	Relaxin Signaling	3.76E-04

Table 4. Shows the top ten most significant pathways of the significant differentially expressed genes across all disease conditions. A comparison of the significant pathways in two comparisons, Neovascular AMD vs Normal and Neovascular AMD vs Intermediate AMD with the top ten shown for each comparison.

Gene splicing differences among AMD stages and tissue types

Differential splicing was observed for 1,154 genes within the retina and for 629 genes within the RPE/choroid in a comparison of neovascular AMD and normal tissues (**Fig 4**). Fewer differentially spliced genes were observed for comparisons of intermediate AMD vs. neovascular AMD (810 in retina, 608 in RPE/choroid) and intermediate AMD vs. normal (210 in retina, 177 in RPE/choroid). Only a small proportion of the 629 differentially spliced genes in the RPE choroid were also differentially expressed in group comparisons: 113 neovascular AMD vs. normal (18.0%), 98 intermediate AMD vs. neovascular AMD (16.1%), and 6 intermediate AMD vs. normal (3.4%). There were no overlapping differentially expressed and spliced genes within the retina. A much larger number of genes in the retina were differentially spliced than in the RPE for all group comparisons.

Allele Specific Expression (ASE)

According to annotation information for published AMD genome-wide association studies included in the NHGRI-EBI Catalog (https://www.ebi.ac.uk/gwas/home; accessed 3/28/17), 12 AMD-associated SNPs are located in coding regions of *APOE* (1), *ARMS2* (1), *C2* (1), *C3* (2), *CFB* (1), *CFH* (4), *CFI* (1), and *PLA2G12A* (1), and therefore were investigated for allele specific expression (**Table 5**). No heterozygotes were found in our sample for *CFH* rs121913059, *CFI* rs141853578, *C3* rs147859257, or *APOE* rs429358. We found no expression of *ARMS2* in either the RPE/choroid or neural retina and therefore we could not investigate the coding SNP rs10490924. For those heterozygotes showing mono-allelic expression (n=6), *CFH* rs10754199 was used

to confirm heterozygotes for *CFH* coding SNPs rs10661170 and rs1061147 (r2 = 1 for rs10754199 and both coding SNPs), *CFB* rs2242572 was used to confirm heterozygous genotypes for *CFB* rs641153 (r2 = 1), and *C3* rs1047286 was used to confirm the heterozygous genotype of *C3* rs2230199 (r2 = 0.843). Significant ASE was detected within individuals at 4 SNPs: *CFH* rs1061170 (Y402H), *CFH* rs1061147, *CFB* rs641153, and *C3* rs2230199. Specifically, for *CFH* rs1061170 we found significant ASE within 2/6 intermediate AMD RPE samples, and 1/7 normal RPE samples. None of the four neovascular AMD RPE heterozygotes showed ASE, noting that there were 10 or fewer reads for these samples in the retina data. For rs1061147, significant ASE was observed within 5/6 intermediate AMD RPE samples, 3/4 neovascular RPE samples, and 7/7 normal RPE samples. These same heterozygotes had 10 or fewer reads among the retina data. The single heterozygote for *CFB* rs641153 (a normal sample) showed significant ASE within the RPE tissue. There were 10 or fewer reads for this SNP in macula retina. There was significant ASE for *C3* rs2230199 within 2/3 intermediate AMD RPE samples, 0/1 neovascular AMD RPE samples, and 2/2 normal RPE samples. These same heterozygotes had 10 or fewer reads in retina tissue.

Table 5. Allele Specific Expression (ASE) of known AMD associated SNPs

			Individuals with Significant ASE (p<.05)*					
SNP	Location	#Hets	Intermediate AMD Retina	Neovascular Retina	Normal Retina	Intermediate AMD RPE	Neovascular RPE	Normal RPE
CFH rs1061147	chr1:196654324	18	0/0	0/0	0/0	5/6	3/4	7/7
CFH rs1061170	chr1:196659237	18	0/0	0/0	0/0	2/6	0/4	1/7
CFH rs35292876	chr1:196706642	1	0/0	0/0	0/0	0/1	0/0	0/0
CFH rs121913059	chr1:196716375	0	0/0	0/0	0/0	0/0	0/0	0/0
PLA2G4A rs2285714	chr4:110638810	15	0/1	0/1	0/3	0/3	0/0	0/1
CFI rs141853578	chr4:110685820	0	0/0	0/0	0/0	0/0	0/0	0/0
C2 rs9332739	chr6:31903804	4	0/0	0/0	0/0	0/1	0/0	0/2
CFB rs641153	chr6:31914180	6	0/0	0/0	0/0	0/0	0/0	1/1
ARMS2 rs10490924	chr10:124214448	7	0/0	0/0	0/0	0/0	0/0	0/0
APOE rs429358	chr19:45411941	0	0/0	0/0	0/0	0/0	0/0	0/0
C3 rs147859257	chr19:6718146	0	0/0	0/0	0/0	0/0	0/0	0/0
C3 rs2230199	chr19:6718387	6	0/0	0/0	0/0	2/3	0/1	2/2

Abbreviations: *, Only individuals with greater than 10 reads are counted; SNP, Single Nucleotide Polymorphism; Hets, heterozygotes; RPE, Retinal Pigment Epithelium.

Validation and replication of RNA-Seq findings

We validated our RNA-Seq methodology by choosing genes that varied in fold expression from a range of +20 to -20 (FDR of $p < 0.05$) between the normal RPE/choroid and retina -- *UCHL1, PFKP*, and *LPCAT1* (down-regulated in RPE/choroid vs. retina) and *PDPN, GAS1*, and *CST3* (up-regulated in RPE/choroid vs. retina) -- by real-time qPCR reactions run in triplicate on a subset of samples that were used for the RNA-Seq experiments. We confirmed the direction of effect for five of the six genes examined (data not shown). We were unable to detect *PFKP* expression in the RPE/choroid tissue and therefore this gene could not be validated. Additionally, we were able to replicate all of our top 20 genes from the normal RPE/choroid vs. normal retina by the Human Eye Integration data (https://eyeintegration.nei.nih.gov/). This database is a collection of healthy human RNA-Seq datasets generated from various studies of human eye tissue. To the best of our knowledge, no public database is yet available that contains gene expression data for the macular RPE/choroid tissues for different AMD clinical stages compared with normal macular RPE/choroid.

Discussion

This is the first study using RNA-Seq to demonstrate genes, including a few of those previously associated with AMD risk, and lncRNAs are expressed differently in the macular retina compared to the macular RPE/choroid layers of eyes obtained within six hours of death from persons with intermediate or macular neovascularization or age-

matched controls using a standardized protocol. Evaluation of known coding regions in previously reported GWAS loci demonstrated that significant ASE for *C3*, rs2230199, and *CFH*, rs1061170, occurred in the macula RPE/choroid for normal, and intermediate AMD while ASE for *CFH*, rs1061147, occurred in the macula RPE/choroid for normal, and intermediate and neovascular AMD. The protective variant for *CFB*, rs641153, only demonstrated ASE in the normal macular RPE/choroid. This is also underscored that these genes which function in the complement pathway were shown to be expressed statistically significantly higher in the normal macula RPE/choroid compared to the normal macula retina. Our comprehensive analysis demonstrated differential patterns of gene expression and splicing between diseased and non-diseased macula retina and RPE/choroid. Although the main pathology of AMD is affecting the macula area mainly, there is not many studies that compared the pathological changes occurring at the macula area (RPE/Choroidal) versus the inner retina, the relationship between the tissue types at given stages of disease is not entirely clear, leaving a big gap of knowledge related to this area [58-59]. It is clear that both the retina and RPE/choroid are important to AMD pathophysiology, it has been hypothesized that RPE cell function is more significantly related to AMD pathophysiology than retinal cell function [58, 60-62]. It is interesting to note that while we did not find the majority of the IAMDGC GWAS loci [5] differentially expressed between intermediate AMD and/or neovascular AMD, we did find that 75% of the genes were statistically significantly higher in the macular RPE/choroid compared to the macular retina thus underscoring the importance of tissue and geographic location in elucidating AMD etiology [62].

Of the known previously associated AMD loci [1, 10, 57, 63], none of them showed differential expression between disease states within the macular neural retina tissues. Of the 34 GWAS loci [5], expression differences between disease states were observed for *SPEF2* (between AREDS3 vs. Neo RPE) and *VTN* (between Neo vs. normal RPE/choroid). This suggests that variants in the gene regions showing heritable differences in AMD risk may influence the expression of tissue. A recent proteomic study on serums from patients with and without all types of late AMD (both neovascular and GA), found that *ZBPB, KREMEN2,* and *LINGO1*A were upregulated in diseased patients [64]. We found the expression of these genes to be significantly upregulated when comparing neovascular AMD or intermediate AMD with the normal macula RPE/choroid.

Absence of differential expression of the two genes previously reported to have the largest effect on AMD risk, *CFH* and *ARMS2/HTRA1*, is in agreement with studies demonstrating that *HTRA1* may influence AMD risk at the tRNA level [65-66]. Moreover, while *CFH* did not demonstrate differential gene expression between disease states in our study, *CFH* did demonstrate allele specific expression with both intermediate AMD and neovascular AMD depending on the SNP being interrogated. It may be this unequal expression of alleles at a given variant within the *CFH* gene to the disease pathophysiology of AMD. The mechanisms that underlie ASE are under active investigation and include epigenetics [67] In general, the differentially expressed genes reported here belong to pathways that have been shown to have important roles in AMD pathogenesis, including cholesterol and lipid metabolism (*DPP6, PON1, TIMD4*),

mitochondrial regulation (*MTRNR2L1, TIMD4, IFI27, DISC1FP1*), and pro-inflammatory pro-macrophagic signaling in intermediate AMD [68-71]. Thus, our results also substantiate the possible contribution of macrophages in the late neovascular stage of the disease, as well as the contribution of mitochondrial dysfunction in the onset and progression of neurodegenerative diseases [68, 72]. Furthermore, *TCN2* regulates Vitamin B12 levels by encoding a protein that is part of the Vitamin B pathway, and was found in this study to be upregulated in those with intermediate AMD compared to normal macular RPE/choroid. Circulating low vitamin B12, high total homocysteine, and low folic acid levels are associated with AMD risk, suggesting that a defect in *TCN2* may reduce its ability to bind its partner proteins correctly, thus resulting in overexpression in the RPE/choroid and potentially a role in the subsequent development of large pathogenic drusen [73-78].

A trend was observed when comparing the top ten differentially expressed genes between each RPE comparison. In both the 'intermediate AMD versus normal RPE/choroid' and 'neovascular AMD versus normal RPE/choroid' comparisons, upregulation of *MTRNR2L1* was observed. Between both the 'neovascular AMD versus normal RPE/choroid' and 'intermediate versus neovascular AMD RPE/choroid' comparisons, three differentially expressed genes were shared, all expressed in opposite magnitudes (ie. upregulated in neovascular AMD and intermediate AMD, respectively; downregulated in normal and neovascular AMD, respectively): *RHO, RBP3,* and *RP51092A11.2.* Further investigation of these loci could prove useful for

identifying novel biomarkers to differentiate between, as well as to track disease progression from, the intermediate form of AMD to the neovascular form.

We also observed differential expression of two distinct lncRNAs (*lncRNA AC00124.1* and *lncRNA RP11-240M16.1*) in the RPE/choroid of both intermediate and late-stage AMD patients in comparison to neovascular and normal eyes respectively, although in opposite directions (downregulated and upregulated, respectively). Since one lncRNA (*lncRNA AC000124.1*) was downregulated in intermediate AMD compared to neovascular AMD patients, it may be used as a biomarker for further validating disease progression from intermediate AMD to neovascular AMD. The lncRNA (*lincRNA RP11-240M16.*1) that we observed to be overexpressed in neovascular RPE/choroid compared to normal RPE/choroid may be a biomarker for late-stage disease. Further investigations could include comparing *lncRNA RP11-240M16.1* expression in neovascular versus GA AMD samples. If found to be differentially expressed between neovascular and GA forms of AMD, it be used as a biomarker to further distinguish between the two late-stage forms and could potentially contribute to pathogenesis. MicroRNAs may play an important role in AMD and represent a potential therapeutic target for treatment [79, 80]. The miRNA-146a was downregulated in RPE/choroid donor tissues from neovascular AMD subjects compared to controls. Previously, miRNA-146a was shown to be upregulated in the serum of patients with neovascular AMD [81-83]. Targets of miRNA-146a have been implicated in modulation of the immune response in endothelial tissue including negative regulation of complement factor H [84-86]. While the extent of involvement of the non-coding genome is still being

investigates, miRANs, snoRNAs, and lncRNAs among non-coding RNA types are being found to have key roles in cellular homeostasis, and with disruption leading to human diseases such as cancer [87]. Our study is the first to evaluate these changes in the affected diseased tissue and suggest that there may be tissue differences in the manner in which miRNAs are expressed reinforcing the importance of examining expression in tissues affected directly by AMD. However further studies will need to be conducted in order to characterize fully the role of lncRNAs and miRNAs as biomarkers and determine their potential as therapeutic targets.

Many of our findings substantiate current ideas regarding AMD pathophysiology. Specifically, significant differential expression between disease states was observed for genes involved in lipid metabolism (*PON1*) [88] and inflammation (*TIMD4*, *PON1, DPP6*, *GPR123*)[55,89-90]. In addition, several of these genes have been associated with disease states hypothesized to co-occur more with AMD such as Alzheimer disease (AD) (*PON, SLC1A2, CPE, NME3*)[89-96] and epilepsy (*CHRNB2, SEZ6L2*) [97-99]. This suggests such diseases may have co-occurring pathophysiology as well as occurrence with AMD [99-101]. Our data also suggest a possible overlap in pathophysiology within the vitamin B12 synthesis pathway [101-102] and amyotrophic lateral sclerosis (ALS)[103-104]. Finally, we describe differential expression between intermediate and normal donor eyes of *CDH7,* a gene that was previously found to interact with smoking and be associated with AMD risk [52]. One gene, *MT2L1* (humanin), overlapped between RPE/choroid and retina, and was overexpressed in the intermediate stage of AMD compared to normal. Further studies on *MT2L1* have found

it to serve a protective role in AD [105-107]. A similar circumstance has been noted for the inverse pattern of association of the APOE alleles: the ε4 allele increases risk of AD and the ε2 allele is protective, whereas the effects of these alleles on AMD risk are opposite [5,108-111].

Several genes and pathways were differentially expressed in comparisons of neovascular AMD with both intermediate AMD and normal macula, suggesting that clinical AMD phenotypes may represent a spectrum of molecular pathophysiology with a similar "core" of dysfunction with superimposed changes that dictate end-stage pathology. The majority of genes that were significantly differentially expressed in comparisons of normal macular tissue and intermediate AMD with end-stage neovascular disease participate in injury response (*SLC1A2, SCAMP5, RHO, PIWIL1, TM4SF2, SLC24A1, PTPRN, CPE, CHRNB2, CALB1*, and *CADM2*) and apoptosis (*CPE* and *PTPRN*) [110–116]. Genes identified in the phototransduction pathway (*ARR3*, *CNGA1*, *CNGA3*, *CNGB1*, *GNAT1*, *GNAT2*, *GNB1*, *GNB3*, *GNB5*, *GNGT1*, *GNGT2*, *GRK1*, *GUCA1A*, *GUCA1B*, *GUCA1C*, *GUCY2D*, *GUCY2F*, *OPN1LW*, *OPN1MW*, *OPN1SW*, *PDC*, *PDE6A*, *PDE6B*, *PDE6C*, *PDE6G*, *PDE6H*, *RCVRN*, *RGS9*, *RHO*, *SAG*) in macula of RPE/choroid of neovascular eyes, are important as retinal and choroidal neovascularization are the main causes of major visual impairment. Targeting molecules involved in photoreceptor apoptosis, has been suggested as an avenue for potential therapies to improve vision in neovascular AMD [118]. Pathway analysis of the overlapping DEGs from intermediate AMD vs normal AMD in the RPE/choroid and neovascular AMD vs normal AMD in the RPE/choroid

showed the involvement of previously implicated GWAS hits TGF β signaling as well as BMP4 [119]. Thus, our findings may provide insight into the pathways modifying disease severity and or progression to neovascular end-stage disease.

Notch Signaling, WNT Beta Catenin Signaling, and TGF β signaling genes, as well as genes down-regulated in response to UV light, were down-regulated in the intermediate clinical stage macula compared to normal RPE/choroid macula. Of note, these pathways were not identified in the pathway analysis of differentially expressed genes in the retina comparing eyes from normal donors and persons with intermediate AMD (**Table 4**), and have all been implicated in AMD [57, 66 ,120-133]. IL2/STAT5 signaling, IL6/JAK/STAT3 signaling, and the inflammatory response and epithelial mesenchymal transition were uniquely differentially expressed and upregulated in macular intermediate AMD compared to normal macular retina. Stat3 activation has previously been implicated in AMD pathophysiology, specifically in the neovascular subtype [134-139]. Taken together, these findings suggest that particular genes that function in the pathways of the RPE/choroid are protective in the development of the advanced forms of AMD while expression of STAT3 and/or other genes in inflammatory pathways in the retina may precede the development of late-stage AMD.

Within the RPE/choroid tissues, we identified several genes that were differentially expressed between normal donor eyes and both Intermediate AMD and neovascular AMD, but also, more importantly, gene expression profiles and pathways that were unique to these AMD stages. These observations are consistent with the idea that

mechanisms governing the development of intermediate AMD are different from those influencing progression to neovascular AMD, [57, 140-146] and thus unique therapeutic interventions may be necessary to treat effectively these different forms of AMD. The histological changes that have been associated with neovascular AMD, including the new pathological growth of immature choroidal blood vessels under the retinal pigment epithelium (RPE) and/or in the subretinal space, moving towards the inner retina, transform or destroy the RPE layer resulting in a different histological arrangement of the retina (mixed RPE with retinal tissue) [147-149]. Therefore, understanding the different factors and genetic background involved in neovascularization and the resulting retinal changes are essential in the development of novel treatments for visual impairment. Our findings also underscore the importance of studying both macular tissue types to gain a full understanding of mechanisms leading to AMD. Future studies should focus on single cell and/or single nuclei from well characterized fresh tissue particularly.

In summary, these RNA-Seq and ASE experiments identified novel and established factors contributing to development of intermediate and neovascular AMD. Our results provide insights into underlying biological mechanisms that may differentiate the disease subtypes and into the tissues affected by the disease. It also expands upon previous RNA studies that demonstrated gene expression differences in affected tissues. Our results may provide insight into why some but not all individuals with intermediate AMD progress to the severe forms. If our results are confirmed in larger independent samples, differential gene expression could be implemented as an adjunct

to a prognostic scheme (eg., blood). In order to make this a clinically useful tool, future studies will need to demonstrate equivalency in the same donors of pertinent gene expression patterns in eye tissue and other tissue that is easily accessible in living persons (e.g., blood).

Funding

This research was supported by The Macular Degeneration Foundation, Inc. (Henderson, NV, USA); The University of Utah School of Medicine, Center on Aging Award (Salt Lake City, Utah), The Carl Marshall Reeves & Mildred Almen Reeves, Foundation, Inc. (Fenton, MO, USA), NIH/NEI: 1K08EY031800-01, Unrestricted grant from Research to Prevent Blindness to the Department of Ophthalmology and Visual Sciences – Moran Eye Center, Ira G. Ross and Elizabeth Olmsted Ross Endowed Chair. Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award Number UL1TR0012-05. The content is solely the responsibility of the authors and does not necessarily represent official views of the National Institute of Health.

References

1. Ung C, Lains I, Miller JW, Kim IK. Current Management of Age-Related Macular Degeneration. Adv Exp Med Biol. 2021;1256:295-314. doi: 10.1007/978-3-030-66014-7_12. PMID: 33848007.

2. Michalska-Małecka, K., A. Kabiesz, M. Nowak, and D. Śpiewak. "Age Related Macular degeneration – challenge for Future: Pathogenesis and New Perspectives for the Treatment." European Geriatric Medicine 6, no. 1 (2014;2015;): 69-75.

3. Rosenfeld, P.J.; Brown, D.M.; Heier, J.S.; Boyer, D.S.; Kaiser, P.K.; Chung, C.Y.; Kim, R.Y. Ranibizumab for neovascular age-relatedmacular degeneration.N. Engl. J. Med.2006,355, 1419–14

4. An E, Sen S, Park SK, Gordish-Dressman H, Hathout Y (2010) Identification of novel substrates for the serine protease HTRA1 in the human RPE secretome. Invest Ophthalmol Vis Sci 51: 3379–3386. doi:10.1167/iovs.09-4853.

5. Fritsche LG, Igl W, Bailey JNC, Grassmann F, Sengupta S, et al. (2016) A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. doi:10.1038/ng.3448.

6. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementationwith vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.Arch.Ophthalmol.2001,119, 1417–1436

7. Jaffe, G.J.; Westby, K.; Csaky, K.G.; Monés, J.; Pearlman, J.A.; Patel, S.S.; Joondeph, B.C.; Randolph, J.; Masonson, H.; Rezaei, K.A.C5 inhibitor Avacincaptad pegol for geographic atrophy due to age-related macular degeneration: A randomized pivotal phase2/3 trial.Ophthalmology2021,128, 576–586. [CrossRef]

8. Liao, D.S.; Grossi, F.V.; El Mehdi, D.; Gerber, M.R.; Brown, D.M.; Heier, J.S.; Wykoff, C.C.; Singerman, L.J.; Abraham, P.;Grassmann, F. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration:A randomized phase 2 trial.Ophthalmology2020,127, 186–195

9. Morgan DJ, DeAngelis MM (2014) Differential Gene Expression in Age-Related Macular Degeneration. Cold Spring Harb Perspect Med. doi:10.1101/cshperspect.a017210.

10. Li M, Zauhar RJ, Grazal C, Curcio CA, DeAngelis MM, et al. (n.d.) RNA expression in human retina. Hum Mol Genet. Available: https://academic.oup.com/hmg/article/doi/10.1093/hmg/ddx219/3895136/RNA-expression-in-human-retina. Accessed 31 July 2017.

11. Ratnapriya R, Sosina OA, Starostik MR, et al. Author Correction: Retinal transcriptome and eQTL analyses identify genes associated with age-related macular degeneration. Nat Genet. 2019;51(6):1067. doi:10.1038/s41588-019-0430-y

12. Kim, E. J., Grant, G. R., Bowman, A. S., Haider, N., Gudiseva, H. V., & Chavali, V. (2018). Complete Transcriptome Profiling of Normal and Age-Related Macular Degeneration Eye Tissues Reveals Dysregulation of Anti-Sense Transcription. Scientific reports, 8(1), 3040. https://doi.org/10.1038/s41598-018-21104-7

13. Menon M, Mohammadi S, Davila-Velderrain J, et al. Single-cell transcriptomic atlas of the human retina identifies cell types associated with age-related macular degeneration. Nat Commun. 2019;10(1):4902. Published 2019 Oct 25. doi:10.1038/s41467-019-12780-8

14. Voigt AP, Mulfaul K, Mullin NK, et al. Single-cell transcriptomics of the human retinal pigment epithelium and choroid in health and macular degeneration. Proc Natl Acad Sci U S A. 2019;116(48):24100-24107. doi:10.1073/pnas.1914143116

15. Saddala MS, Lennikov A, Mukwaya A, Fan L, Hu Z, Huang H. Transcriptome-wide analysis of differentially expressed chemokine receptors, SNPs, and SSRs in the age-related

macular degeneration. Hum Genomics. 2019;13(1):15. Published 2019 Mar 20. doi:10.1186/s40246-019-0199-1

16. Orozco LD, Chen HH, Cox C, et al. Integration of eQTL and a Single-Cell Atlas in the Human Eye Identifies Causal Genes for Age-Related Macular Degeneration. Cell Rep. 2020;30(4):1246-1259.e6. doi:10.1016/j.celrep.2019.12.082

17. Llavona, P., Pinelli, M., Mutarelli, M., Marwah, V. S., Schimpf-Linzenbold, S., Thaler, S., Yoeruek, E., Vetter, J., Kohl, S., & Wissinger, B. (2017). Allelic Expression Imbalance in the Human Retinal Transcriptome and Potential Impact on Inherited Retinal Diseases. Genes, 8(10), 283. https://doi.org/10.3390/genes8100283

18. Silveira AC, Morrison MA, Ji F, Xu H, Reinecke JB, et al. (2010) Convergence of linkage, gene expression and association data demonstrates the influence of the RAR-related orphan receptor alpha (RORA) gene on neovascular AMD: a systems biology based approach. Vision Res 50: 698–715. doi:10.1016/j.visres.2009.09.016.

19. Liang Q, Dharmat R, Owen L, et al. Single-nuclei RNA-seq on human retinal tissue provides improved transcriptome profiling. Nat Commun. 2019;10(1):5743. Published 2019 Dec 17. doi:10.1038/s41467-019-12917-9

20. Owen, L. A., Shakoor, A., Morgan, D. J., Hejazi, A. A., McEntire, M. W., Brown, J. J., Farrer, L. A., Kim, I., Vitale, A., & DeAngelis, M. M. (2019). The Utah Protocol for Postmortem Eye Phenotyping and Molecular Biochemical Analysis. Investigative ophthalmology & visual science, 60(4), 1204–1212. https://doi.org/10.1167/iovs.18-24254

21. Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10: 57–63. doi:10.1038/nrg2484.

22. Zhao S, Fung-Leung W-P, Bittner A, Ngo K, Liu X (2014) Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. PLoS ONE 9: e78644. doi:10.1371/journal.pone.0078644.

23. Batista PJ, Chang HY (2013) Long noncoding RNAs: cellular address codes in development and disease. Cell 152: 1298–1307. doi:10.1016/j.cell.2013.02.012.

24. Bhan A, Mandal SS (2014) Long noncoding RNAs: emerging stars in gene regulation, epigenetics and human disease. ChemMedChem 9: 1932–1956. doi:10.1002/cmdc.201300534.

25. Lau P, Frigerio CS, De Strooper B (2014) Variance in the identification of microRNAs deregulated in Alzheimer's disease and possible role of lincRNAs in the pathology: the need of larger datasets. Ageing Res Rev 17: 43–53. doi:10.1016/j.arr.2014.02.006.

26. Webb A, Papp AC, Curtis A, Newman LC, Pietrzak M, et al. (2015) RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles. BMC Genomics 16: 990. doi:10.1186/s12864-015-2207-8.

27. Au, Elizabeth D. et al. 2017. "Characterization of LincRNA Expression in the Human Retinal Pigment Epithelium and Differentiated Induced Pluripotent Stem Cells." PLoS ONE 12(8): 1–17.

28. Whitmore SS, Wagner AH, DeLuca AP, Drack AV, Stone EM, et al. (2014) Transcriptomic analysis across nasal, temporal, and macular regions of human neural retina and RPE/choroid by RNA-Seq. Exp Eye Res 129: 93–106. doi:10.1016/j.exer.2014.11.001.

29. Farkas MH, Grant GR, White JA, Sousa ME, Consugar MB, et al. (2013) Transcriptome analyses of the human retina identify unprecedented transcript diversity and 3.5 Mb of novel transcribed sequence via significant alternative splicing and novel genes. BMC Genomics 14: 486. doi:10.1186/1471-2164-14-486.

30. Li M, Jia C, Kazmierkiewicz KL, Bowman AS, Tian L, et al. (2014) Comprehensive analysis of gene expression in human retina and supporting tissues. Hum Mol Genet 23: 4001–4014. doi:10.1093/hmg/ddu114.

31. Handa JT, Bowes Rickman C, Dick AD, et al. A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration. Nat Commun. 2019;10(1):3347. Published 2019 Jul 26. doi:10.1038/s41467-019-11262-1

32. Ross J (1995) mRNA stability in mammalian cells. Microbiol Rev 59: 423–450.

34. Malik KJ, Chen C-D, Olsen TW (2003) Stability of RNA from the retina and retinal pigment epithelium in a porcine model simulating human eye bank conditions. Invest Ophthalmol Vis Sci 44: 2730–2735.

35. Beach TG, Sue LI, Walker DG, Roher AE, Lue L, et al. (2008) The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank 9: 229–245. doi:10.1007/s10561-008-9067-2.

36. Trabzuni D, Ryten M, Walker R, Smith C, Imran S, et al. (2011) Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. J Neurochem 119: 275–282. doi:10.1111/j.1471-4159.2011.07432.x.

37. Gaur U, Li K, Mei S, Liu G (2013) Research progress in allele-specific expression and its regulatory mechanisms. J Appl Genet 54: 271–283. doi:10.1007/s13353-013-0148-y.

38. Tan AC, Fan J-B, Karikari C, Bibikova M, Garcia EW, et al. (2008) Allele-specific expression in the germline of patients with familial pancreatic cancer: An unbiased approach to cancer gene discovery. Cancer biology & therapy 7: 135.

39. Ben-David E, Shohat S, Shifman S (2014) Allelic expression analysis in the brain suggests a role for heterogeneous insults affecting epigenetic processes in autism spectrum disorders. Hum Mol Genet 23: 4111–4124. doi:10.1093/hmg/ddu128.

40. Li Y, Grupe A, Rowland C, Nowotny P, Kauwe JSK, et al. (2006) DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet 15: 2560–2568. doi:10.1093/hmg/ddl178.

41. Guda K, Natale L, Lutterbaugh J, Wiesner GL, Lewis S, et al. (2009) Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients. Cancer Res 69: 4959–4961. doi:10.1158/0008-5472.CAN-09-0225.

42. Valle L, Serena-Acedo T, Liyanarachchi S, Hampel H, Comeras I, et al. (2008) Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science 321: 1361–1365. doi:10.1126/science.1159397.

43. Lambert J-C, Pérez-Tur J, Dupire M-J, Galasko D, Mann D, et al. (1997) Distortion of Allelic Expression of Apolipoprotein E in Alzheimer's Disease. Hum Mol Genet 6: 2151–2154. doi:10.1093/hmg/6.12.2151.

44. Age-Related Eye Disease Study Research Group (2001) The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol 132: 668–681.

45. Bowes Rickman C, Ebright JN, Zavodni ZJ, Yu L, Wang T, et al. (2006) Defining the human macula transcriptome and candidate retinal disease genes using EyeSAGE. Invest Ophthalmol Vis Sci 47: 2305–2316. doi:10.1167/iovs.05-1437.

46. Zheng W, Reem RE, Omarova S, Huang S, DiPatre PL, et al. (2012) Spatial distribution of the pathways of cholesterol homeostasis in human retina. PLoS ONE 7: e37926. doi:10.1371/journal.pone.0037926.

47. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15: 550. doi:10.1186/s13059-014-0550-8.

48. Castel SE, Levy-Moonshine A, Mohammadi P, Banks E, Lappalainen T (2015) Tools and best practices for data processing in allelic expression analysis. Genome Biology 16: 195. doi:10.1186/s13059-015-0762-6.

49. Krämer, A., Green, J., Pollard, Jr., J., and Tugendreich, S. (2014) Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 30(4):523–30.

50. Sharon D, Blackshaw S, Cepko CL, Dryja TP (2002) Profile of the genes expressed in the human peripheral retina, macula, and retinal pigment epithelium determined through serial

analysis of gene expression (SAGE). Proc Natl Acad Sci U S A 99: 315–320. doi:10.1073/pnas.012582799.

51. Sreekumar PG, Ishikawa K, Spee C, Mehta HH, Wan J, et al. (2016) The Mitochondrial-Derived Peptide Humanin Protects RPE Cells From Oxidative Stress, Senescence, and Mitochondrial DysfunctionHumanin Protects RPE Cells From Oxidative Stress. Invest Ophthalmol Vis Sci 57: 1238–1253. doi:10.1167/iovs.15-17053.

52. Naj AC, Scott WK, Courtenay MD, Cade WH, Schwartz SG, et al. (2013) Genetic factors in nonsmokers with age-related macular degeneration revealed through genome-wide gene-environment interaction analysis. Ann Hum Genet 77: 215–231. doi:10.1111/ahg.12011.

53. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, et al. (2013) Discovery and refinement of loci associated with lipid levels. Nat Genet 45: 1274–1283. doi:10.1038/ng.2797.

54. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466: 707–713. doi:10.1038/nature09270.

55. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, et al. (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 41: 56–65. doi:10.1038/ng.291.

56. Fransen E, Bonneux S, Corneveaux JJ, Schrauwen I, Di Berardino F, et al. (2015) Genome-wide association analysis demonstrates the highly polygenic character of age-related hearing impairment. Eur J Hum Genet 23: 110–115. doi:10.1038/ejhg.2014.56.

57. Morrison MA, Silveira AC, Huynh N, Jun G, Smith SE, et al. (2011) Systems biology-based analysis implicates a novel role for vitamin D metabolism in the pathogenesis of age-related macular degeneration. Hum Genomics 5: 538–568.

58. Bhutto I, Lutty G (2012) Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's

membrane/choriocapillaris complex. Mol Aspects Med 33: 295–317. doi:10.1016/j.mam.2012.04.005.

59. Jones BW, Kondo M, Terasaki H, Lin Y, McCall M, Marc RE. Retinal remodeling. Jpn J Ophthalmol. 2012;56(4):289-306. doi:10.1007/s10384-012-0147-2

60. Wang L, Clark ME, Crossman DK, Kojima K, Messinger JD, et al. (2010) Abundant lipid and protein components of drusen. PLoS ONE 5: e10329. doi:10.1371/journal.pone.0010329.

61. Curcio CA, Johnson M, Rudolf M, Huang J-D (2011) The oil spill in ageing Bruch membrane. Br J Ophthalmol 95: 1638–1645. doi:10.1136/bjophthalmol-2011-300344.

62. Zanzottera EC, Messinger JD, Ach T, Smith RT, Curcio CA (2015) Subducted and melanotic cells in advanced age-related macular degeneration are derived from retinal pigment epithelium. Invest Ophthalmol Vis Sci 56: 3269–3278. doi:10.1167/iovs.15-16432.

63. Owen LA, Morrison MA, Ahn J, Woo SJ, Sato H, et al. (2014) FLT1 genetic variation predisposes to neovascular AMD in ethnically diverse populations and alters systemic FLT1 expression. Invest Ophthalmol Vis Sci 55: 3543–3554. doi:10.1167/iovs.14-14047.

64. Emilsson V, Gudmundsson EF, Jonmundsson T, Jonssen BG, Twarog M, et al. (2022) A proteogenomic signature of age-related macular degeneration in blood. Nat Commun 13: 3401. doi: 10.1038/s41467-022-31085-x.

65. Jacobo SMP, Deangelis MM, Kim IK, Kazlauskas A (2013) Age-Related Macular Degeneration-Associated Silent Polymorphisms in HtrA1 Impair Its Ability To Antagonize Insulin-Like Growth Factor 1. Mol Cell Biol 33: 1976–1990. doi:10.1128/MCB.01283-12.

66. Friedrich U, Datta S, Schubert T, Plössl K, Schneider M, et al. (2015) Synonymous variants in HTRA1 implicated in AMD susceptibility impair its capacity to regulate TGF-β signaling. Hum Mol Genet 24: 6361–6373. doi:10.1093/hmg/ddv346.

67. Zauhar R, Biber J, Jabri Y, Kim M, Hu J, Kaplan L, Pfaller AM, Schäfer N, Enzmann V, Schlötzer-Schrehardt U, Straub T, Hauck SM, Gamlin PD, McFerrin MB, Messinger J, Strang CE, Curcio CA, Dana N, Pauly D, Grosche A, Li M, Stambolian D (2022). As in Real Estate,

Location Matters: Cellular Expression of Complement Varies Between Macular and Peripheral Regions of the Retina and Supporting Tissues. Front Immunol. 15;13:895519. doi: 10.3389/fimmu.2022.895519. PMID: 35784369; PMCID: PMC9240314.

68. Lin, M. T., & Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature, 443*(7113), 787-795. doi:10.1038/nature05292

69. The FANTOM Consortium and the RIKEN PMI and CLST (dgt) (2014) A promoter-level mammalian expression atlas. Nature 507: 462–470. doi:10.1038/nature13182.

70. Ardeljan D, Chan C-C (2013) Aging is not a disease: distinguishing age-related macular degeneration from aging. Prog Retin Eye Res 37: 68–89. doi:10.1016/j.preteyeres.2013.07.003.

71. Lad EM, Cousins SW, Van Arnam JS, Proia AD (2015) Abundance of infiltrating CD163+ cells in the retina of postmortem eyes with dry and neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 253: 1941–1945. doi:10.1007/s00417-015-3094-z.

72. Lückoff A, Caramoy A, Scholz R, Prinz M, Kalinke U, et al. (2016) Interferon-beta signaling in retinal mononuclear phagocytes attenuates pathological neovascularization. EMBO Mol Med 8: 670–678. doi:10.15252/emmm.201505994.

73. Gopinath B, Flood VM, Rochtchina E, Wang JJ, Mitchell P (2013) Homocysteine, folate, vitamin B-12, and 10-y incidence of age-related macular degeneration. Am J Clin Nutr 98: 129–135. doi:10.3945/ajcn.112.057091.

74. Huang P, Wang F, Sah BK, Jiang J, Ni Z, et al. (2015) Homocysteine and the risk of age-related macular degeneration: a systematic review and meta-analysis. Sci Rep 5: 10585. doi:10.1038/srep10585.

75. Christen WG, Glynn RJ, Chew EY, Albert CM, Manson JE (2009) Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. Arch Intern Med 169: 335–341. doi:10.1001/archinternmed.2008.574.

76. Elmasry K, Mohamed R, Sharma I, Elsherbiny NM, Liu Y, Al-Shabrawey M, et al. Epigenetic modifications in hyperhomocysteinemia: potential role in diabetic retinopathy and age-related macular degeneration. Oncotarget. 2018;9(16):12562-90.

77. Ibrahim AS, Mander S, Hussein KA, Elsherbiny NM, Smith SB, Al-Shabrawey M, et al. Hyperhomocysteinemia disrupts retinal pigment epithelial structure and function with features of age-related macular degeneration. Oncotarget. 2016;7(8):8532-45.

78. Tawfik A, Samra YA, Elsherbiny NM, Al-Shabrawey M. Implication of Hyperhomocysteinemia in Blood Retinal Barrier (BRB) Dysfunction. Biomolecules. 2020;10(8).

79. Zhang C, Owen LA, Lillvis JH, Zhang SX, Kim IK, DeAngelis MM. AMD Genomics: Non-Coding RNAs as Biomarkers and Therapeutic Targets. J Clin Med. 2022;11(6).

80. Berber P, Grassmann F, Kiel C, Weber BH. An Eye on Age-Related Macular Degeneration: The Role of MicroRNAs in Disease Pathology. Mol Diagn Ther. 2017;21(1):31-43.

81. Ménard C, Rezende FA, Miloudi K, Wilson A, Tétreault N, Hardy P, et al. MicroRNA signatures in vitreous humour and plasma of patients with exudative AMD. Oncotarget. 2016;7(15):19171-84.

82. Romano GL, Platania CBM, Drago F, Salomone S, Ragusa M, Barbagallo C, et al. Retinal and Circulating miRNAs in Age-Related Macular Degeneration: An In vivo Animal and Human Study. Front Pharmacol. 2017;8:168.

83. Litwińska Z, Sobuś A, Łuczkowska K, Grabowicz A, Mozolewska-Piotrowska K, Safranow K, et al. The Interplay Between Systemic Inflammatory Factors and MicroRNAs in Age-Related Macular Degeneration. Front Aging Neurosci. 2019;11:286.

84. Hill JM, Zhao Y, Clement C, Neumann DM, Lukiw WJ. HSV-1 infection of human brain cells induces miRNA-146a and Alzheimer-type inflammatory signaling. Neuroreport. 2009;20(16):1500-5.

85. Satoh J. MicroRNAs and their therapeutic potential for human diseases: aberrant microRNA expression in Alzheimer's disease brains. J Pharmacol Sci. 2010;114(3):269-75.

86. Hsieh CH, Rau CS, Jeng SF, Lin CJ, Chen YC, Wu CJ, et al. Identification of the potential target genes of microRNA-146a induced by PMA treatment in human microvascular endothelial cells. Exp Cell Res. 2010;316(7):1119-26.

87. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861-74.

88. Szemraj M, Bielecka-Kowalska A, Oszajca K, Krajewska M, Goś R, et al. (2015) Serum MicroRNAs as Potential Biomarkers of AMD. Med Sci Monit 21: 2734–2742. doi:10.12659/MSM.893697.

89. Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661–678. doi:10.1038/nature05911.

90. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, et al. (2007) TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study. N Engl J Med 357: 1199–1209. doi:10.1056/NEJMoa073491.

91. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, et al. (2008) Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 14: 575–581. doi:10.2119/2008-00056.Liu.

92. Carter CJ (2007) Convergence of genes implicated in Alzheimer’s disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis. Neurochem Int 50: 12–38. doi:10.1016/j.neuint.2006.07.007.

93. Erlich PM, Lunetta KL, Cupples LA, Huyck M, Green RC, et al. (2006) Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum Mol Genet 15: 77–85. doi:10.1093/hmg/ddi428.

94. Erlich PM, Lunetta KL, Cupples LA, Abraham CR, Green RC, et al. (2012) Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease. Neurobiol Aging 33: 1015.e7-23. doi:10.1016/j.neurobiolaging.2010.08.003.

95. Woltjer RL, Duerson K, Fullmer JM, Mookherjee P, Ryan AM, et al. (2010) Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J Neuropathol Exp Neurol 69: 667–676. doi:10.1097/NEN.0b013e3181e24adb.

96. Takahashi K, Kong Q, Lin Y, Stouffer N, Schulte DA, et al. (2015) Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer's disease. J Exp Med 212: 319–332. doi:10.1084/jem.20140413.

97. Plá V, Paco S, Ghezali G, Ciria V, Pozas E, et al. (2013) Secretory sorting receptors carboxypeptidase E and secretogranin III in amyloid β-associated neural degeneration in Alzheimer's disease. Brain Pathol 23: 274–284. doi:10.1111/j.1750-3639.2012.00644.x.

98. Shimizu-Nishikawa K, Kajiwara K, Kimura M, Katsuki M, Sugaya E (1995) Cloning and expression of SEZ-6, a brain-specific and seizure-related cDNA. Brain Res Mol Brain Res 28: 201–210.

99. Díaz-Otero F, Quesada M, Morales-Corraliza J, Martínez-Parra C, Gómez-Garre P, et al. (2008) Autosomal dominant nocturnal frontal lobe epilepsy with a mutation in the CHRNB2 gene. Epilepsia 49: 516–520. doi:10.1111/j.1528-1167.2007.01328.x.

100. Logue MW, Schu M, Vardarajan BN, Farrell J, Lunetta KL, et al. (2014) Search for age-related macular degeneration risk variants in Alzheimer disease genes and pathways. Neurobiol Aging 35: 1510.e7-18. doi:10.1016/j.neurobiolaging.2013.12.007.

101. Sinha S, Satishchandra P, Santosh V, Gayatri N, Shankar SK (2004) Neuronal ceroid lipofuscinosis: a clinicopathological study. Seizure 13: 235–240. doi:10.1016/S1059-1311(03)00163-8.

102. Grarup N, Sulem P, Sandholt CH, Thorleifsson G, Ahluwalia TS, et al. (2013) Genetic architecture of vitamin B12 and folate levels uncovered applying deeply sequenced large datasets. PLoS Genet 9: e1003530. doi:10.1371/journal.pgen.1003530.

103. Mitchell ES, Conus N, Kaput J (2014) B vitamin polymorphisms and behavior: evidence of associations with neurodevelopment, depression, schizophrenia, bipolar disorder and cognitive decline. Neurosci Biobehav Rev 47: 307–320. doi:10.1016/j.neubiorev.2014.08.006.

104. Blauw HM, van Rheenen W, Koppers M, Van Damme P, Waibel S, et al. (2012) NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. Hum Mol Genet 21: 2497–2502. doi:10.1093/hmg/dds064.

105. Matsuoka M (2011) Humanin signal for Alzheimer's disease. J Alzheimers Dis 24 Suppl 2: 27–32. doi:10.3233/JAD-2011-102076.

106. Matsuoka M (2015) Protective effects of Humanin and calmodulin-like skin protein in Alzheimer's disease and broad range of abnormalities. Mol Neurobiol 51: 1232–1239. doi:10.1007/s12035-014-8799-1.

107. Chai G-S, Duan D-X, Ma R-H, Shen J-Y, Li H-L, et al. (2014) Humanin attenuates Alzheimer-like cognitive deficits and pathological changes induced by amyloid β-peptide in rats. Neurosci Bull 30: 923–935. doi:10.1007/s12264-014-1479-3.

108. Baird PN, Guida E, Chu DT, Vu HTV, Guymer RH (2004) The epsilon2 and epsilon4 alleles of the apolipoprotein gene are associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 45: 1311–1315.

109. Levy O, Lavalette S, Hu SJ, Housset M, Raoul W, et al. (2015) APOE Isoforms Control Pathogenic Subretinal Inflammation in Age-Related Macular Degeneration. J Neurosci 35: 13568–13576. doi:10.1523/JNEUROSCI.2468-15.2015.

110. Shen L, Hoffmann TJ, Melles RB, Sakoda LC, Kvale MN, et al. (2015) Differences in the Genetic Susceptibility to Age-Related Macular Degeneration Clinical Subtypes. Invest Ophthalmol Vis Sci 56: 4290–4299. doi:10.1167/iovs.15-16533.

111. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, et al. (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278: 1349–1356.

112. Cai T, Xie J, She JX, Notkins AL (2001) Analysis of the coding and promoter regions of the autoantigen IA-2 in subjects with and without autoantibodies to IA-2. Diabetes 50: 2406–2409.

113. Lan MS, Wasserfall C, Maclaren NK, Notkins AL (1996) IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 93: 6367–6370.

114. Borg H, Fernlund P, Sundkvist G (1997) Protein tyrosine phosphatase-like protein IA2-antibodies plus glutamic acid decarboxylase 65 antibodies (GADA) indicates autoimmunity as frequently as islet cell antibodies assay in children with recently diagnosed diabetes mellitus. Clin Chem 43: 2358–2363.

115. Kubosaki A, Miura J, Notkins AL (2004) IA-2 is not required for the development of diabetes in NOD mice. Diabetologia 47: 149–150. doi:10.1007/s00125-003-1252-z.

116. Elbers CC, Onland-Moret NC, Franke L, Niehoff AG, van der Schouw YT, et al. (2007) A strategy to search for common obesity and type 2 diabetes genes. Trends Endocrinol Metab 18: 19–26. doi:10.1016/j.tem.2006.11.003.

117. Cawley NX, Zhou J, Hill JM, Abebe D, Romboz S, et al. (2004) The carboxypeptidase E knockout mouse exhibits endocrinological and behavioral deficits. Endocrinology 145: 5807–5819. doi:10.1210/en.2004-0847.

118. Miller JW (2011) Treatment of age-related macular degeneration: Beyond VEGF. Jpn J Ophthalmol 54: 523–528. doi:10.1007/s10384-010-0863-4.

119. Ibrahim AS, Hussein K, Wang F, Wan M, Saad N, Essa M, et al. (2020) Bone Morphogenetic Protein (BMP)4 But Not BMP2 Disrupts the Barrier Integrity of Retinal Pigment

Epithelia and Induces Their Migration: A Potential Role in Neovascular Age-Related Macular Degeneration. J Clin Med. 9(7).

120. Lueck K, Hennig M, Lommatzsch A, Pauleikhoff D, Wasmuth S (2012) Complement and UV-irradiated photoreceptor outer segments increase the cytokine secretion by retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 53: 1406–1413. doi:10.1167/iovs.11-8889.

121. Chalam KV, Khetpal V, Rusovici R, Balaiya S (2011) A review: role of ultraviolet radiation in age-related macular degeneration. Eye Contact Lens 37: 225–232. doi:10.1097/ICL.0b013e31821fbd3e.

122. Sur A, Kesaraju S, Prentice H, Ayyanathan K, Baronas-Lowell D, et al. (2014) Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-α. Proc Natl Acad Sci USA 111: 16754–16759. doi:10.1073/pnas.1419576111.

123. Ahmad I, Balasubramanian S, Del Debbio CB, Parameswaran S, Katz AR, et al. (2011) Regulation of ocular angiogenesis by Notch signaling: implications in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 52: 2868–2878. doi:10.1167/iovs.10-6608.

124. Liu L, Zhou X, Kuang X, Long C, Liu W, et al. (2017) The inhibition of NOTCH2 reduces UVB-induced damage in retinal pigment epithelium cells. Mol Med Rep 16: 730–736. doi:10.3892/mmr.2017.6625.

125. Yamamoto H, Fara AF, Dasgupta P, Kemper C (2013) CD46: the “multitasker” of complement proteins. Int J Biochem Cell Biol 45: 2808–2820. doi:10.1016/j.biocel.2013.09.016.

126. Zhou T, Hu Y, Chen Y, Zhou KK, Zhang B, et al. (2010) The pathogenic role of the canonical Wnt pathway in age-related macular degeneration. Invest Ophthalmol Vis Sci 51: 4371–4379. doi:10.1167/iovs.09-4278.

127. Burke JM (2008) Epithelial phenotype and the RPE: is the answer blowing in the Wnt? Prog Retin Eye Res 27: 579–595. doi:10.1016/j.preteyeres.2008.08.002.

128. Tuo J, Wang Y, Cheng R, Li Y, Chen M, et al. (2015) Wnt signaling in age-related macular degeneration: human macular tissue and mouse model. J Transl Med 13: 330. doi:10.1186/s12967-015-0683-x.

129. Katoh M (2013) Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int J Mol Med 32: 763–767. doi:10.3892/ijmm.2013.1444.

130. Li Y, Song D, Song Y, Zhao L, Wolkow N, et al. (2015) Iron-induced Local Complement Component 3 (C3) Up-regulation via Non-canonical Transforming Growth Factor (TGF)-β Signaling in the Retinal Pigment Epithelium. J Biol Chem 290: 11918–11934. doi:10.1074/jbc.M115.645903.

131. Zhang L, Lim SL, Du H, Zhang M, Kozak I, et al. (2012) High temperature requirement factor A1 (HTRA1) gene regulates angiogenesis through transforming growth factor-β family member growth differentiation factor 6. J Biol Chem 287: 1520–1526. doi:10.1074/jbc.M111.275990.

132. P, Gutteridge A, Impey E, Storer RI, Owen RM, et al. (2016) Targeting the cAMP and Transforming Growth Factor-β Pathway Increases Proliferation to Promote Re-Epithelialization of Human Stem Cell-Derived Retinal Pigment Epithelium. Stem Cells Transl Med 5: 925–937. doi:10.5966/sctm.2015-0247.

133. Radeke MJ, Radeke CM, Shih Y-H, Hu J, Bok D, et al. (2015) Restoration of mesenchymal retinal pigmented epithelial cells by TGFβ pathway inhibitors: implications for age-related macular degeneration. Genome Med 7: 58. doi:10.1186/s13073-015-0183-x.

134. Chen M, Lechner J, Zhao J, Toth L, Hogg R, et al. (2016) STAT3 Activation in Circulating Monocytes Contributes to Neovascular Age-Related Macular Degeneration. Curr Mol Med 16: 412–423.

135. Nakamura R, Sene A, Santeford A, Gdoura A, Kubota S, et al. (2015) IL10-driven STAT3 signalling in senescent macrophages promotes pathological eye angiogenesis. Nat Commun 6: 7847. doi:10.1038/ncomms8847.

136. Patel AK, Hackam AS (2014) A novel protective role for the innate immunity Toll-Like Receptor 3 (TLR3) in the retina via Stat3. Mol Cell Neurosci 63: 38–48. doi:10.1016/j.mcn.2014.09.004.

137. Fasler-Kan E, Wunderlich K, Hildebrand P, Flammer J, Meyer P (2005) Activated STAT 3 in choroidal neovascular membranes of patients with age-related macular degeneration. Ophthalmologica 219: 214–221. doi:10.1159/000085730.

138. Izumi-Nagai K, Nagai N, Ozawa Y, Mihara M, Ohsugi Y, et al. (2007) Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. Am J Pathol 170: 2149–2158. doi:10.2353/ajpath.2007.061018.

139. Sun Y, Lin Z, Liu C-H, Gong Y, Liegl R, et al. (2017) Inflammatory signals from photoreceptor modulate pathological retinal angiogenesis via c-Fos. J Exp Med 214: 1753–1767. doi:10.1084/jem.20161645.

140. Jun G, Nicolaou M, Morrison MA, Buros J, Morgan DJ, et al. (2011) Influence of ROBO1 and RORA on risk of age-related macular degeneration reveals genetically distinct phenotypes in disease pathophysiology. PLoS ONE 6: e25775. doi:10.1371/journal.pone.0025775.

141. Itty S, Day S, Lyles KW, Stinnett SS, Vajzovic LM, et al. (2014) Vitamin D deficiency in neovascular versus nonneovascular age-related macular degeneration. Retina (Philadelphia, Pa) 34: 1779–1786. doi:10.1097/IAE.0000000000000178.

142. Friberg TR, Bilonick RA, Brennen PM (2012) Risk factors for conversion to neovascular age-related macular degeneration based on longitudinal morphologic and visual acuity data. Ophthalmology 119: 1432–1437. doi:10.1016/j.ophtha.2012.02.048.

143. Liew G, Joachim N, Mitchell P, Burlutsky G, Wang JJ (2016) Validating the AREDS Simplified Severity Scale of Age-Related Macular Degeneration with 5- and 10-Year Incident Data in a Population-Based Sample. Ophthalmology 123: 1874–1878. doi:10.1016/j.ophtha.2016.05.043.

144. Chew EY, Clemons TE, Agrón E, Sperduto RD, Sangiovanni JP, et al. (2013) Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology 120: 1604–1611.e4. doi:10.1016/j.ophtha.2013.01.021.

145. Sardell RJ, Persad PJ, Pan SS, Whitehead P, Adams LD, et al. (2016) Progression Rate From Intermediate to Advanced Age-Related Macular Degeneration Is Correlated With the Number of Risk Alleles at the CFH Locus. Invest Ophthalmol Vis Sci 57: 6107–6115. doi:10.1167/iovs.16-19519.

146. DeAngelis MM, Owen LA, Morrison MA, Morgan DJ, Li M, et al. (n.d.) Genetics of Age Related Macular Degeneration (AMD). Hum Mol Genet. Available: https://academic.oup.com/hmg/article/doi/10.1093/hmg/ddx228/3867129/Genetics-of-Age-Related-Macular-Degeneration-AMD. Accessed 31 July 2017.

147. Pfeiffer RL, Marc RE, Jones BW. Persistent remodeling and neurodegeneration in late-stage retinal degeneration. Prog Retin Eye Res. 2020;74:100771.

148. Jones BW, Pfeiffer RL, Ferrell WD, Watt CB, Tucker J, Marc RE. Retinal Remodeling and Metabolic Alterations in Human AMD. Front Cell Neurosci. 2016;10:103.

149. Jones BW, Marc RE, Pfeiffer RL. Retinal Degeneration, Remodeling and Plasticity. In: Kolb H, Fernandez E, Nelson R, editors. Webvision: The Organization of the Retina and Visual System. Salt Lake City (UT): University of Utah Health Sciences Center

Copyright: © 2022 Webvision . 1995.

Figure Legends

Fig 1. Hierarchal clustering analysis (HCA) of 47 donor eye samples from the RPE/choroid and retina. Rows and columns represent each individual sample against the rest of the samples.

Fig 2. Differentially expressed genes. Each circle shows the number of genes with increased expression in that disease state, i.e., 1085 genes were upregulated in the macula RPE/choroid of neovascular eyes when compared to normal eyes and 119 genes were upregulated in the macula RPE/choroid of normal eyes compared to neovascular eyes.

Fig 3. Overlap of differentially expressed genes. Each circle represents the number of significant differentially expressed genes in RPE/choroid when comparing normal eyes with both neovascular AMD and AREDS3. The overlap between these two circles shows the number of common genes between these two conditions.

Fig 4. Differentially spliced genes. The number of genes showing differential splice sites among each of the comparisons examined.

Supporting Information

S1 Table. Significant differential gene expression. Tables indicating all significant differential gene expression using a medium significance threshold (fold change > |1.5| and $p < .05$). There are separate tabs for each tissue and disease comparison.


Color key
and Histogram
Control
0
20
40
0
100
200
300
Value
Normal_Retina2
Normal_Retina4
AREDS3_Retina4
AREDS3_Retina5
NeoAMD_Retina2
AREDS3_Retina6
AREDS3_Retina3
NeoAMD_Retina4
Normal_Retina7
Normal_Retina5
Normal_Retina3
Normal_Retina1
Normal_Retina8
Normal_Retina6
NeoAMD_Retina1
AREDS3_Retina1
AREDS3_Retina2
Normal_Retina0
AREDS3_Retina0
Normal_Retina9
NeoAMD_Retina5
NeoAMD_Retina0
NeoAMD_Retina3
AREDS3_Retina7
AREDS3_RPE7
NeoAMD_RPE1
Normal_RPE7
Normal_RPE5
AREDS3_RPE6
AREDS3_RPE0
Normal_RPE8
Normal_RPE6
AREDS3_RPE3
Normal_RPE4
Normal_RPE2
AREDS3_RPE4
Normal_RPE0
NeoAMD_RPE2
AREDS3_RPE1
Normal_RPE1
Normal_RPE3
AREDS3_RPE5
NeoAMD_RPE0
AREDS3_RPE2

a. Macula RPE/choroid



b. Macula Retina



MACULAR RPE/CHOROID




AREDS 3 vs. Neo
608
810
Neo vs. Normal
629
1154
AREDS 3 vs. Normal
177
210
0
200
400
600
800
1000
1200
1400
1600
1800
2000
Number of Genes
RPE/Choroid
Retina